Therapeutic efficacy of antibody drugs in patients with severe viral infections and COVID-19

ABSTRACT

The review summarizes information on the therapeutic efficacy of antibody preparations in severe viral infections with a detailed analysis of their activity in COVID-19. The pathogenesis and drug therapy of coronavirus infection are briefly considered. Medicinal properties of blood plasma of convalescents and possible reasons for its insufficient, in some cases, efficiency are analyzed. Various points of view on the advisability of creating and using hyperimmune drugs containing a high titer of antibodies to COVID-19 are discussed. On the example of gabriglobin, a domestic immunoglobulin for intravenous administration, which has a high therapeutic activity in hemorrhagic fever with renal syndrome, cytomegalovirus infection, atypical pneumonia and septic conditions, it is hypothesized that for the treatment of many severe viral diseases, including COVID-19, it is possible to use of conventional, "normal" immunoglobulin preparations, which have a population-averaged antibody titer and many cross-reacting antibodies to a wide range of infectious agents. Copyright © 2022, Dynasty Publishing House. All rights reserved.